Accurate diagnosis, Gleason grading and staging of prostate cancer, and prudent use of ancillary tests are critical for management of prostate cancer patients. However, error in diagnosing, grading and reporting prostate cancer has remained a significant problem in clinical practice, with diagnostic errors that potentially impact clinical management in 1-15% of prostate biopsies.
Gleason grading system has undergone significant modification and a new grading system has been proposed, yet the adoption of these changes in clinical practice is slow. New entities of important clinical significance, such as intraductal carcinoma, have been described. There have been tremendous advances in the understanding of molecular and genetic mechanisms in prostate carcinogenesis and progression which has led to development of multigene genetic and genomic tests. However, there has been a lack of understanding of the new entities and molecular diagnostic tests among practicing pathologists. Target Audience
Practicing academic and community pathologists, and pathologists-in-training Learning Objectives
Upon completion of this educational activity, learners will be able to:
Continuing Medical Education and Maintenance of Certification
- Review histological criteria for diagnosing prostate cancer and use of immunohistochemistry markers.
- Review benign mimickers of prostate cancer and cancer that mimics benign prostate lesions.
- Update on recent modifications of Gleason system and the novel grading system (grade grouping).
- Identify the clinical relevant pathological parameters that should be included in the surgical pathology report.
- Learn the new advances in molecular mechanisms in prostate carcinogenesis/progression and clinically relevant genetic tests.
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 6.75 AMA PRA Category 1 CreditsTM
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 6.25 SAM credit hours. Disclosures
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Cristina Magi-Galluzzi, M.D., Ph.D., Ming Zhou, M.D., Ph.D., Mark Rubin, M.D., Kiril Trpkov, M.D., Jonathan Epstein, M.D., Peter Humphrey, M.D., Adeboye Osunkoya, M.D., David Grignon, M.D., Andy Evans, M.D., Ph.D., Samson Fine, M.D., Jesse McKenney, M.D., Glen Kristiansen, M.D.
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.